Evorpacept

DB17573InvestigationalProtein Based Therapies

Evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).

Mechanism: Evorpacept binds, blocks, and antagonizes the human cell surface antigen CD47.
Curator reviewed · 2 references
Also known as: A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG · Cd47/sirpa-blocking agent alx148 · Sirpa variant alx148
Code names: ALX-148 · LGGL-ALX-148

Resolves to

Compound

UNIIX7K762X1IJCAS2484949-51-9

Targets

Q08722CD47

What you can answer from here — as of June 16, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evorpacept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account